Figure 5

A-1, B-1, C-1 and D-1 showed the distribution of percentages of apoptosis;, and A-2, B-2, C-2 and D-2 showed the distribution of percentages of cell cycle for Eca-109 cells treated with oxLDL or ADM alone and both of them combined after 48 h of the treatment. For cell cycle: A-2: 67.37 ± 5.49%, 22.03 ± 0.73% and 10.60 ± 0.26% in the G1/G0, S and G2/M phase of control; B-2: 59.45 ± 4.53%, 29.86 ± 1.77% and 10.69 ± 0.62% in the G1/G0, S and G2/M phase of the oxLDL; C-2: 24.12 ± 3.64%, 62.59 ± 4.29% and 13.28 ± 1.45% in the G1/G0, S and G2/M phase of the ADM; D-2: 8.73 ± 2.48%, 15.61 ± 5.17% and 75.66 ± 3.64% in the G1/G0, S and G2/M phase of the above oxLDL and ADM combined, respectively. The proportions of apoptosis and phase of cell cycle in 40 μg/ml oxLDL + 0.1 μg/ml ADM group were significant higher than that in other groups, p < 0.05. Dose: A-1 and A-2: control group; B-1 and B-2: 40 μg/ml oxLDL; C-1 and C-2: 0.1 μg/ml ADM; D-1 and D-2: 40 μg/ml oxLDL + 0.1 μg/ml ADM. Abbreviation: ADM, adriamycin.